Roivant Sciences (ROIV) Cash & Equivalents (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Cash & Equivalents came in at $1.4 billion in Q1 2026, down 47.73% YoY from $2.7 billion in Q1 2025, and down 3.99% on a QoQ basis from $1.5 billion in Q4 2025.
Roivant Sciences (ROIV) Cash & Equivalents (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Cash & Equivalents data on file, last reported at $1.4 billion in Q1 2026.
- Quarterly Cash & Equivalents fell 47.73% year-over-year to $1.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (down 47.73% YoY) and the FY2026 annual result came in at $1.4 billion, down 47.73% from the prior year.
- Cash & Equivalents eased to $1.4 billion in Q1 2026, from $1.5 billion in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $6.7 billion in Q4 2023 to a low of $99.1 million in Q4 2024.
- A 5-year average of $2.4 billion and a median of $1.6 billion in 2022 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2024 — Cash & Equivalents sank 98.52% — and 2025, when it jumped 1391.95%.
- Tracing ROIV's Cash & Equivalents over 5 years: stood at $1.5 billion in 2022, then soared by 338.64% to $6.7 billion in 2023, then slumped by 98.52% to $99.1 million in 2024, then jumped by 1391.95% to $1.5 billion in 2025, then fell by 3.99% to $1.4 billion in 2026.
- The last three Cash & Equivalents figures came in at $1.4 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 1.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.25 Bn |
| Mar 31, 2026 | 1.42 Bn |
| Dec 31, 2025 | 1.48 Bn |
| Sep 30, 2025 | 1.24 Bn |
| Jun 30, 2025 | 1.24 Bn |
| Mar 31, 2025 | 2.72 Bn |
| Dec 31, 2024 | 99.08 Mn |
| Sep 30, 2024 | 1.96 Bn |
| Jun 30, 2024 | 5.70 Bn |
| Mar 31, 2024 | 6.49 Bn |
| Dec 31, 2023 | 6.70 Bn |
| Sep 30, 2023 | 1.40 Bn |
| Jun 30, 2023 | 1.43 Bn |
| Mar 31, 2023 | 1.68 Bn |
| Dec 31, 2022 | 1.53 Bn |
| Sep 30, 2022 | 1.60 Bn |
| Jun 30, 2022 | 1.94 Bn |
| Mar 31, 2022 | 2.06 Bn |
| Dec 31, 2021 | 2.20 Bn |
| Sep 30, 2021 | 2.50 Bn |